The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age

HIV Clinical Trials
Jaime H VeraA Winston

Abstract

Antiretroviral safety and efficacy and may differ in older versus younger HIV-infected patients. The objective of this study was to assess the pharmacokinetic (PK) profile in older HIV-infected subjects (>60 years) switching combination antiretroviral therapy (cART) to a raltegravir (RAL) containing regimen. Nineteen HIV-infected patients over 60 years of age on effective cART (HIV-RNA < 50 copies/ml) were enrolled in this prospective 24-week study. On day 1, patients switched to tenofovir/emtricitabine (245/200 mg once daily) and RAL (400 mg twice daily). On day 28, intensive PK sampling was undertaken in a fasted state and RAL plasma concentrations determined. Neurocognitive function was assessed at baseline and week 24 using a neuropsychological battery. RAL PK parameters were compared to those of two younger historical HIV-infected control groups that received twice-daily RAL co-administered with darunavir/ritonavir (DRV/r) 800/100 once daily by nonlinear mixed effects modelling. In HIV-infected subjects over the age of 60 (mean ± SD age: 66 ± 3.4 years, n = 19) switching to a RAL containing regimen, we observed no safety concerns, no plasma virological rebounds, and no differences in RAL apparent oral clearance when compar...Continue Reading

References

Dec 18, 2003·British Journal of Clinical Pharmacology·A A Mangoni, S H D Jackson
Dec 14, 2005·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Lucette A J CysiqueBruce J Brew
Jun 27, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kelem KassahunLarissa A Wenning
Apr 25, 2008·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jean-Marie PoirierPatrice Jaillon
Nov 18, 2008·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Katherine WildJeffrey Kaye
Jan 28, 2009·BMJ : British Medical Journal·Steven G Deeks, Andrew N Phillips
May 12, 2010·Journal of Clinical Pharmacology·Diana M BrainardMarian Iwamoto
Jun 3, 2010·Antiviral Therapy·Catia MarzoliniUNKNOWN Swiss HIV Cohort Study
Jan 7, 2011·Journal of Clinical Pharmacology·Diana M BrainardMarian Iwamoto
Mar 9, 2011·Journal of Clinical Pharmacology·Dario CattaneoEmilio Clementi
Sep 20, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Akil JacksonMarta Boffito
Oct 15, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Barbara HasseUNKNOWN Swiss HIV Cohort Study
Dec 1, 2011·The Journal of Antimicrobial Chemotherapy·Dario CattaneoEmilio Clementi
Jun 16, 2012·American Journal of Public Health·John T BrooksJonathan Mermin
Apr 23, 2013·Journal of General Internal Medicine·Carol HoltzmanUNKNOWN , and the HOPS Investigators

❮ Previous
Next ❯

Citations

Dec 6, 2017·Pharmacogenomics·Jessica CusatoAntonio D'Avolio
Jan 25, 2020·Current Opinion in HIV and AIDS·Sarah Czarna Mann, Jose R Castillo-Mancilla
Apr 30, 2021·Expert Opinion on Drug Metabolism & Toxicology·Andrea CalcagnoStefano Bonora

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.